Skip to main content

Miconazole Side Effects

Medically reviewed by Drugs.com. Last updated on Mar 13, 2024.

Applies to miconazole: buccal mucosa tablet.

Common side effects of miconazole

Some side effects of miconazole may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common side effects

  • change in taste
  • diarrhea
  • dry mouth
  • headache
  • itching skin
  • loss of taste
  • nausea
  • pain, redness, and swelling of the gums
  • sores on the tongue
  • toothache

Less common side effects

  • abdominal or stomach pain
  • loss of appetite
  • pain
  • upper abdominal or stomach pain
  • weakness

Serious side effects of miconazole

Along with its needed effects, miconazole may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking miconazole:

Less common side effects

  • body aches or pain
  • cough
  • difficulty with breathing
  • ear congestion
  • fever or chills
  • headache
  • loss of voice
  • lower back or side pain
  • nasal congestion
  • painful or difficult urination
  • pale skin
  • runny nose
  • sneezing
  • sore throat
  • troubled breathing with exertion
  • unusual bleeding or bruising
  • unusual tiredness or weakness

Rare side effects

For healthcare professionals

Applies to miconazole: buccal tablet, intravenous solution.

General adverse events

The overall safety of the buccal tablets was assessed in 480 adult subjects, including 315 HIV-infected subjects, 147 subjects with head and neck cancer, and 18 healthy subjects. Discontinuation due to side effects occurred in 0.6% of subjects overall.

The most common side effects reported with the oral gel were nausea, abnormal product taste, vomiting, oral discomfort, regurgitation, dry mouth, and dysgeusia.

Although the IV product has been discontinued in the US, side effects associated with this formulation have been included.[Ref]

Local

Buccal tablets:

IV formulation:

Local side effects (including oral discomfort, oral burning, oral pain, gingival pain, gingival swelling, gingival pruritus, tongue ulceration, mouth ulceration, glossodynia, dry mouth, application site pain/discomfort, toothache, loss of taste, altered taste) have been reported in 12.1% of HIV-infected patients. Local side effects (including oral discomfort, oral pain, dry mouth, glossodynia, loss of taste, altered taste, tongue ulceration, mouth ulceration, tooth disorder, application site discomfort/pain) have been reported in 9.5% of patients with head and neck cancer.[Ref]

Gastrointestinal

Buccal tablets:

Oral gel:

IV formulation:

Nervous system

Buccal tablets:

Oral gel:

IV formulation:

Respiratory

Buccal tablets:

Oral gel:

Hematologic

Buccal tablets:

Oral gel:

IV formulation:

Increases in INR and bleeding events (e.g., epistaxis, contusion, hematuria, melena, hematemesis, hematoma, hemorrhages) have been reported in patients treated with oral anticoagulants (e.g., warfarin) and this oral gel; some events had fatal outcomes.[Ref]

Other

Buccal tablets:

Oral gel:

IV formulation:

Dermatologic

Buccal tablets:

Oral gel:

IV formulation:

Pruritus (which may have been accompanied by maculopapular rash) has been reported with the IV formulation, and in some cases, severe pruritus developed after weeks of therapy or after therapy was completed.[Ref]

Hepatic

Buccal tablets:

Oral gel:

Hypersensitivity

Buccal tablets:

Oral gel:

IV formulation:

Contact dermatitis has been reported when the IV formulation was used topically.[Ref]

Metabolic

Oral gel:

IV formulation:

Increases in cholesterol and triglycerides reported in patients receiving the IV formulation were due to its vehicle (Cremophor EL [polyethoxylated castor oil]), and were reversible upon discontinuation of the drug. Hyperlipidemia due to Cremophor EL had the atypical appearance of gamma-2 globulin.

Hyponatremia associated with the IV formulation resulted in a mean decrease in sodium of 10 mEq/L, but usually was not a reason to discontinue therapy. This drug was usually administered in normal saline solution to help minimize decreases in sodium.[Ref]

Ocular

Oral gel:

IV formulation:

Cardiovascular

IV formulation:

Cardiac arrhythmias, tachycardia, and cardiac arrest may have been associated with rapid infusion of the drug and due to the Cremophor EL vehicle.[Ref]

Psychiatric

IV formulation:

Renal

IV formulation:

Acute renal failure, possibly due to the IV formulation, was reported in 1 patient with a renal allograft.[Ref]

References

1. Stevens D (1977) "Miconazole in the treatment of systemic fungal infections." Am Rev Respir Dis, 116, p. 801-6

2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

3. Cerner Multum, Inc. "Australian Product Information."

4. (2010) "Product Information. ORAVIG (miconazole)." Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc.

5. Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS (1980) "Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections." Drugs, 19, p. 7-30

6. Wade TR, Jones HE, Chanda JJ (1979) "Intravenous miconazole therapy of mycotic infections." Arch Intern Med, 139, p. 784-6

7. Fischer TJ, Klein RB, Kershnar HE, Borut TC, Stiehm ER (1977) "Miconazole in the treatment of chronic mucocutaneous candidiasis: a preliminary report." J Pediatr, 91, p. 815-9

8. Bodey GP (1988) "Topical and systemic antifungal agents." Med Clin North Am, 72, p. 637-59

9. "Product Information. Monistat 7 (miconazole topical)." Ortho McNeil Pharmaceutical

10. Marmion LC, Desser KB, Lilly RB, Stevens DA (1976) "Reversible thrombocytosis and anemia due to miconazole therapy." Antimicrob Agents Chemother, 10, p. 447-9

11. Barr RJ, Fujita WH, Graham JH (1978) "Eruptive xanthomas associated with intravenous miconazole therapy." Arch Dermatol, 114, p. 1544-5

12. Degreef H, Verhoeve L (1975) "Contact dermatitis to miconazole nitrate." Contact Dermatitis, 1, p. 269-70

13. Fernandez L, Maquiera E, Rodriguez F, Picans I, Duque S (1996) "Systemic contact dermatitis from miconazole." Contact Dermatitis, 34, p. 217

14. Fainstein V, Bodey GP (1980) "Cardiorespiratory toxicity due to miconazole." Ann Intern Med, 93, p. 432-3

15. Perret CM, Happle R (1988) "Contact allergy to miconazole." Contact Dermatitis, 19, p. 75

16. Baes H (1991) "Contact sensitivity to miconazole with ortho-chloro cross-sensitivity to other imidazoles." Contact Dermatitis, 24, p. 89-93

17. Wade TR, Jones HE, Artis WA (1979) "Irritant and allergic reactions to topically applied Micatin cream." Contact Dermatitis, 5, p. 168-70

18. Raulin C, Frosch PJ (1988) "Contact allergy to imidazole antimycotics." Contact Dermatitis, 18, p. 76-80

19. Naito HK, McHenry MC, Lewis LA (1980) "Drug-induced dyslipoproteinemia: a report of two cases." Clin Chem, 26, p. 163-8

20. Rose HD, Roth DA, Barboriak JJ (1979) "Hyperlipidemia related to miconazole therapy." Ann Intern Med, 91, p. 491-2

21. Bagnarello AG, Lewis LA, McHenry MC, Weinstein AJ, Naito HK, McCullough AJ, Lederman RJ, Gavan TL (1977) "Unusual serum lipoprotein abnormality induced by the vehicle of miconazole." N Engl J Med, 296, p. 497-9

22. Coley KC, Crain JL (1997) "Miconazole-induced fatal dysrhythmia." Pharmacotherapy, 17, p. 379-82

23. Lai KN, Newton M, Seymour A, Pugsley D, Jones T (1981) "Miconazole treatment after renal transplantation." Lancet, 4, p. 48-9

Frequently asked questions

Further information

Miconazole side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.